1945950-21-9 Usage
Description
PDD00017273 is a chemical compound that serves as a chemical probe against poly(ADP-ribose) glycohydrolase (PARG). It is designed to inhibit DNA repair with differential pharmacological properties compared to olaparib, making it a valuable tool in the study and potential treatment of various conditions related to DNA repair mechanisms.
Uses
Used in Pharmaceutical Research:
PDD00017273 is used as a chemical probe for [application reason] in the pharmaceutical industry. Its ability to inhibit DNA repair through targeting PARG makes it a promising candidate for the development of novel therapeutic strategies against diseases with aberrant DNA repair mechanisms.
Used in DNA Repair Inhibition:
PDD00017273 is used as a DNA repair inhibitor for studying the role of PARG in DNA repair processes. By inhibiting PARG, PDD00017273 can help researchers understand the underlying mechanisms of DNA repair and potentially develop targeted therapies for conditions where DNA repair is a critical factor.
Used in Cancer Research:
In the field of cancer research, PDD00017273 is used as a chemical probe to investigate the potential of PARG inhibition in cancer treatment. Its differential pharmacological properties compared to olaparib may offer new insights into the development of more effective cancer therapies, particularly for tumors with specific DNA repair deficiencies.
Check Digit Verification of cas no
The CAS Registry Mumber 1945950-21-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,9,4,5,9,5 and 0 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1945950-21:
(9*1)+(8*9)+(7*4)+(6*5)+(5*9)+(4*5)+(3*0)+(2*2)+(1*1)=209
209 % 10 = 9
So 1945950-21-9 is a valid CAS Registry Number.
1945950-21-9Relevant articles and documents
First-in-class chemical probes against poly(ADP-ribose) glycohydrolase (PARG) inhibit DNA repair with differential pharmacology to olaparib
James, Dominic I.,Smith, Kate M.,Jordan, Allan M.,Fairweather, Emma E.,Griffiths, Louise A.,Hamilton, Nicola S.,Hitchin, James R.,Hutton, Colin P.,Jones, Stuart,Kelly, Paul,McGonagle, Alison E.,Small, Helen,Stowell, Alexandra I. J.,Tucker, Julie,Waddell, Ian D.,Waszkowycz, Bohdan,Ogilvie, Donald J.
, p. 3179 - 3190 (2016)
The enzyme poly(ADP-ribose) glycohydrolase (PARG) performs a critical role in the repair of DNA single strand breaks (SSBs). However, a detailed understanding of its mechanism of action has been hampered by a lack of credible, cell-active chemical probes. Herein, we demonstrate inhibition of PARG with a small molecule, leading to poly(ADP-ribose) (PAR) chain persistence in intact cells. Moreover, we describe two advanced, and chemically distinct, cell-active tool compounds with convincing on-target pharmacology and selectivity. Using one of these tool compounds, we demonstrate pharmacology consistent with PARG inhibition. Further, while the roles of PARG and poly(ADP-ribose) polymerase (PARP) are closely intertwined, we demonstrate that the pharmacology of a PARG inhibitor differs from that observed with the more thoroughly studied PARP inhibitor olaparib. We believe that these tools will facilitate a wider understanding of this important component of DNA repair and may enable the development of novel therapeutic agents exploiting the critical dependence of tumors on the DNA damage response (DDR).
